

Economy

Fiscal cost of new stimulus measures likely to be ~0.3% of GDP

On 28 Jun 2021, the Finance Minister announced a fresh round of stimulus measures to support the economy after the second wave of Covid-19. The measures consist of three pillars: 'economic relief', 'health' and 'impetus to growth and employment'. While the announced size of the package was ~Rs 6.3trn (or ~2.8% of nominal GDP in FY22), the actual fiscal outgo in FY22 is likely to be ~Rs 684bn (~0.3% of GDP). Our analysis of the measures shows that 'economic relief', 'health', and 'impetus to growth and employment' pillars account for 60%, 2% and 38% of the total announcements. However, in terms of fiscal outgo, they account for 0%, 22% and 78% respectively.

- ▶ **FM announces new round of stimulus:** Finance Minister Nirmala Sitharaman announced fresh stimulus measures on 28 Jun 2021 to combat the economic impact of the second wave of Covid-19. The announced size of the stimulus was Rs 6.3trn or ~2.8% of the estimated nominal GDP for FY22. The package was based on three pillars: economic relief from the pandemic, support to the health sector and impetus for growth and employment.
- ▶ **Announced size of the package ~Rs 6.3trn; actual fiscal outgo in FY22 estimated at Rs 684bn:** While the announced size of the package was ~Rs 6.3trn, the actual fiscal outgo in FY22 is likely to be much lower. This is because of three reasons: (i) some of the measures included in the package were announced earlier (e.g. extension of free food grains till Nov 2021, additional allocation for fertilizer subsidy) (ii) like the earlier stimulus packages, this package has also relied heavily on government-guaranteed loans which don't have any upfront fiscal cost and (iii) some of the measures are spread over five years, splitting the fiscal costs over a longer timeframe.
- ▶ **'Economic Relief' pillar mostly based on guarantees; actual fiscal outgo meagre Rs 1bn:** The 'economic relief' pillar constituted measures to (i) support sectors ravaged by the pandemic (such as health infrastructure, microfinance institutions, travel and tourism sector), (ii) incentivise new employment generation (by subsidising PF contribution), (iii) continuation of free food grain distribution to the poor, and (iv) additional allocation for fertilizer subsidy. The total announced size of this pillar is Rs 3.76trn or almost 60% of the total package. However, out of these measures, the last two viz. free food grains to the poor till Nov 2021 and additional allocation of fertiliser subsidy were announced earlier in the months leading up to yesterday's package. Hence, excluding these old measures, the quantum of fresh measures comes to Rs 2.67trn. Since this package mostly consists of guaranteed loans (which do not result in immediate fiscal outgo), its actual impact on the fisc in FY22 is estimated at just Rs 1bn.
- ▶ **'Health' pillar aims to augment pediatric healthcare infrastructure; fiscal outgo Rs 150bn:** The second pillar, 'health', had just one measures aimed at augmenting pediatric healthcare infrastructure, availability of ICU beds, oxygen supply and other critical healthcare needs. While the total outgo under this pillar is pegged at Rs 232bn, centre's share is estimated at Rs 150bn.
- ▶ **'Impetus for growth and employment' pillar most significant in terms of stimulus; outgo seen at Rs 533bn:** The third pillar, 'Impetus for growth and employment', is the most important pillar in terms of stimulus. It consists of financial assistance to DISCOMS, measures to boost to exports, and investment in broadband. In terms of announced size, this pillar accounts for Rs 2.37trn or 38% of the package. However, in terms of estimated fiscal outgo, it is the most significant pillar accounting for Rs 533bn or 78% of the estimated fiscal cost of this package.

Research Analyst:

Anagha Deodhar

anagha.deodhar@icicisecurities.com
+91 22 2277 7622

Table 1: Pillar-wise size and expected fiscal outgo

Pillar	Announced size (Rs bn)	Expected fiscal outgo, FY22 (Rs bn)
Economic Relief From Pandemic	3,762	1
Health	150	150
Impetus for Growth & Employment	2,377	533
Total	6,289	684

Source: Ministry of Finance, I-Sec Research

Table 2: Details of stimulus package announced on 28 Jun 2021

Announcement	Details	Duration	Total amount	Estimated fiscal cost in FY22
Pillar 1: Economic Relief From Pandemic				
Rs 1.1trn Loan Guarantee Scheme for COVID Affected Sectors	1. Allocation for health sector: Rs 500bn. Scheme aimed at scaling up medical infrastructure in underserved areas. Guarantee coverage (50% for expansion, 75% for new projects). 2. Allocation for other sectors: Rs 600bn. Interest rate capped at 7.95%.		Rs 1.1trn	0
Additional Rs 1.5trn for Emergency Credit Line Guarantee Scheme (ECLGS)	Increased allocation of ECLGS scheme to Rs 4.5trn from Rs 3trn announced earlier. Admissible guarantee limit and loan amount proposed to be increased above existing level of 20% of outstanding on each loan.		Rs 1.5trn	0
Credit Guarantee Scheme for MFIs	Guarantee cover for funding provided to MFIs/NBFC-MFIs till March 31, 2022 or till guarantees for an amount of Rs.75bn are issued, whichever is earlier.	Guarantee up to 75% of default amount for up to 3 years	Rs 75bn	0
Financial Support to Tourism Sector	Loans with 100 % guarantee up to the following limits: • Rs 1,000,000 for TTS • Rs 100,000 for licensed tourist guides.		-	0
Free Tourist Visa	First 500,000 Tourists Visas will be issued free of charge.	Till 31 Mar 2022 or till 500,000 visas are issued, whichever is earlier	Rs 1bn	Rs 1bn
Extension of Atmanirbhar Bharat Rozgar Yojana	Subsidy provided on PF contribution of new employees. Approved outlay Rs 228bn, utilisation Rs 9bn.	Scheme extended from Jun 2021 to Mar 2022	-	0
Additional Subsidy for DAP & P&K fertilizers (Announced earlier)	Additional amount of Rs 147bn: Rs 91bn for DAP and Rs 56bn for NPK*	FY22	Rs 147bn	Rs 147bn
Extension of Pradhan Mantri Gareeb Kalyan Anna Yojana (Announced earlier)	Free food grains of 5 kg to 800mn NFSA beneficiaries from May to November 2021*	May to Nov 2021	Rs 938bn	Rs 938bn
Public Health				
Scheme for short term emergency preparedness for paediatric care	Increased availability of ICU beds, oxygen supply, equipment, medicines.	-	Rs 232bn	Rs 150bn
Impetus for Growth & Employment				
Release of Climate Resilient Special Traits Varieties	Focus on new bio-fortified crop varieties having high nutrients like protein, iron, zinc, vitamin-A.	-	0	0
Revival of North Eastern Regional Agricultural Marketing Corporation	Revival package of Rs 0.77bn proposed for financial restructuring and infusion of funds to NERAMAC	-	Rs 0.77bn	Rs 0.77bn
Boost for Project Exports through National Export Insurance Account	Additional corpus of Rs 330bn to NEIA over 5 years	FY22 to FY26	Rs 330bn	Rs 66bn

Announcement	Details	Duration	Total amount	Estimated fiscal cost in FY22
Boost to Export Insurance Cover	Equity infusion of Rs 880bn in ECGC over 5 years	FY22 to FY26	Rs 880bn	Rs 176bn
Broadband through BharatNet PPP Model	Additional Rs 190bn being provided for BharatNet	-	Rs 190bn	Rs 92bn
Extension of Tenure of PLI Scheme for Large Scale Electronics Manufacturing	Tenure extended till FY26.	Till FY26	0	0
Reform Based Result Linked Power Distribution Scheme	Financial assistance to DISCOMS for infrastructure creation and up-gradation. Total allocation Rs 3trn, Central share Rs 976bn	-	Rs 976bn	Rs 195bn
PPP Projects and Asset Monetisation	Speedy clearance of projects	-	0	0
Total			Rs 6.3trn	Rs 684bn

Source: Ministry of Finance, I-Sec Research. * not included in new announcements.

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)

BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

ANALYST CERTIFICATION

I/We, Anagha Deodhar (MA Economics) authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as an entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.